Skip to content

Addressing Racial Disparities in Opioid Overdose Using Peer Recovery Coach Training and mHealth Platform

Addressing Racial Disparities in Opioid Overdose Deaths Using an Open Source Peer Recovery Coach Training and Multimodal Mobile Health Platform

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06573476
Enrollment
180
Registered
2024-08-27
Start date
2025-06-25
Completion date
2027-03-15
Last updated
2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorder

Keywords

Opioid Use Disorder, Peer Recovery Coach, Cultural Structural Humility, mHealth, People With Opioid Use Disorder, OUD, PWOUD, mHealth Intervention

Brief summary

The study aims to adapt an existing Cultural Structural Humility (CSH) training into a video format for peer recovery coaches (PRCs) and refine an AI-driven texting tool to reinforce the training. After refining these tools using user-centered design, a pilot test will be conducted to assess their impact on the uptake of opioid treatment and social services. The study will also evaluate the feasibility and effectiveness of the intervention to inform future large-scale trials.

Detailed description

The purpose of this study is to adapt an evidence-supported, currently staff-led Cultural Structural Humility (CSH) training to an interactive video format (7 brief video modules) for PRCs (Aim 1) while concurrently, refining a validated AI-driven texting tool that will newly reinforce core CSH training principles (Aim 2) that focus upon cultural and structural determinants of health (CSDH). After completing iterative refinement per user-centered design strategies based on the Technology Acceptance Model (TAM) for Aim 1 and 2, the investigators will pilot test CSH-trained PRCs delivering telephone based care/services coordination combined with refined AI-driven texting to enhance uptake of MOUD services, and social services (Aim 3). Aim 3 is sized for feasibility testing, final 'de-bugging' of the platform, and informing study conceptualization for a future large-scale efficacy trial. In this R34, the intervention effects will be assessed on the primary clinical outcome (i.e., receipt of buprenorphine), secondary outcome (i.e., uptake of social services), and implementation of the proposed multimodal intervention platform per the RE-AIM framework.

Interventions

BEHAVIORALPRC supported text + AI driven CSDH-enhanced text

In interventional Arm-1, PRC-supported text check-ins to participants (3x/week) will be provided by PRC study staff in addition to automated AI-driven texts. The PRC will personalize text "check-ins" to participants based on: (a) baseline CSDH needs (e.g., food insecurity, legal aid); (b) initial intake visit in primary care or challenges with service entry; and (c) content outlined in the CSH training addressing emerging participant challenges.

BEHAVIORALAI driven CSDH-enhanced text only

In interventional Arm-2, participants will receive the AI-driven CSDH-enhanced text messaging only. Participants in this arm will not receive text support from the PRC.

BEHAVIORALTreatment as Usual (TAU)

In Arm-3, the control group, individuals randomized to the control arm will receive treatment as usual (i.e., verbal instructions and NYC Dept of Health pamphlets detailing access to OUD and social services). No services will be provided except for social/clinical service referrals given at the end of each REDCap visit.

Sponsors

Friends Research Institute, Inc.
Lead SponsorOTHER
Nathan Kline Institute for Psychiatric Research
CollaboratorOTHER
NYU Langone Health
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* ≥18 years of age * fluent in English * self-reported non-prescription opioid use \<30 days prior to consent * provision of informed consent * planned stay in NYC ≥3 months * Black and/or Latinx race/ethnicity * positive urine toxicology for opioids per EMR records or study staff administered random saliva drug testing * diagnosis of OUD per the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) * self-reported interest in initiating buprenorphine in primary care, or elsewhere.

Exclusion criteria

* inability to comprehend text content written at a 3rd grade reading level * physical or visual disability preventing mobile phone use

Design outcomes

Primary

MeasureTime frameDescription
Estimated Rate of PRC-PWUO Contact3 monthsThe number of contacts between Peer Recovery Coaches (PRC) and People Who Use Opioids (PWUO), measured through communication logs.
Rate of AI-Driven Texting Use Among PWUO3 monthsThe frequency of AI-driven text interactions initiated by PWUO, captured through software logs.
Change in Felt and/or Anticipated Stigma3 monthsThe change in felt and/or anticipated stigma pre- and post-intervention, measured by a validated stigma assessment questionnaire.
Amount of time to Initial Receipt of Buprenorphine (Self-Reported)3 monthsThe time (in days) to the initial receipt of buprenorphine, as self-reported by participants.
The Amount of Self-Reported Social Services Use3 monthsThe self-reported utilization of social services at baseline, 1 month, and 3 months, addressing social determinants of health (SDH) to assess intervention effect sizes.
Cost (Amount of Money) of Implementing and Sustaining the Multimodal Intervention3 monthsThe associated cost of implementing and sustaining the multimodal intervention, including cost-per quality-adjusted life year (QALY) and cost-per opioid use disorder (OUD) treatment days.

Secondary

MeasureTime frameDescription
The Amount of Participants That Retain in Treatment3 monthsThe number of participants continuously retained in buprenorphine treatment over a 12-week period, assessed at the 12-week mark.

Countries

United States

Contacts

CONTACTAna Ventuneac, PHd
aventuneac@startny.org718-260-2931
STUDY_DIRECTORAna Ventuneac

START Treatment and Recovery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026